Cosmo Pharmaceuticals N.V.

COPN

NL0011832936

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:10 2024-05-10 am EDT			5-day change	1st Jan Change
70.8 ^CHF	-0.28%		-1.94%	+39.10%

Apr. 26	Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024	CI
Apr. 25	Cosmo Pharmaceuticals Names New CEO, Chairman	MT

EQS-Adhoc : Cosmo Full-Year Report 2020: Cosmo -2-

March 26, 2021 at 02:04 am EDT

----------------------------------------------------------------------------------------------------------------------- End of ad hoc announcement -----------------------------------------------------------------------------------------------------------------------


Language:     English 
Company:      Cosmo Pharmaceuticals N.V. 
              Riverside 2, Sir John Rogerson's 
              Dublin 2 Dublin 
              Ireland 
Phone:        + 353 1 817 0370 
E-mail:       info@cosmopharma.com 
Internet:     https://www.cosmopharma.com/ 
ISIN:         NL0011832936 
Listed:       SIX Swiss Exchange 
EQS News ID:  1178750 
 
End of Announcement EQS Group News Service 
=------------

1178750 26-March-2021 GMT/BST

(END) Dow Jones Newswires

March 26, 2021 02:03 ET (06:03 GMT)

Latest news about Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024	Apr. 26	CI
Cosmo Pharmaceuticals Names New CEO, Chairman	Apr. 25	MT
Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day	Mar. 20
Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024	Mar. 20	CI
Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2024 and Revenue Guidance for 2025	Mar. 20	CI
Transcript : Cosmo Pharmaceuticals N.V., 2023 Earnings Call, Mar 20, 2024	Mar. 20
Cosmo Pharmaceuticals' FY23 Profit, Revenue Drops	Mar. 20	MT
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Cosmo Pharmaceuticals Partner Gets Regulatory Approval for Acne Treatment in Australia	Mar. 19	MT
Berenberg Lifts Price Target on Cosmo Pharmaceuticals, Maintains Buy Recommendation	Jan. 03	MT
Medtronic Expands Partnership With Cosmo Pharmaceuticals Unit	Dec. 11	MT
Cosmo Pharmaceuticals, Medtronic to Boost AI Focus in Expanded Partnership	Dec. 11	MT
Cosmo Pharmaceuticals Redeems EUR175 Million of Bonds due 2023	Dec. 06	MT
Global markets live: Nvidia, Chevron, FedEx, Roche, PepsiCo...	23-10-10
Cosmo Pharmaceuticals Files Marketing Authorization Application in Europe for Topical Acne Treatment	23-10-10	MT
Cosmo Pharmaceuticals Licenses Acne Treatment Winlevi to Hikma in Middle East, North Africa	23-10-02	MT
Cosmo Pharmaceuticals Signs Distribution, Licensing Deals with Glenmark for Acne Cream in Europe, South Africa	23-09-27	MT
Cosmo Pharmaceuticals N.V. and Glenmark Specialty S.A. Announce the Signing of Distribution and License Agreements for Winlevi® in Europe and South Africa	23-09-27	CI
Global markets live: Arm, Amgen, Lloyds, Novo Nordisk, Nestlé...	23-09-04
Cosmo Pharmaceuticals Signs License Deal With Adalvo for Rifamycin	23-09-04	MT
Cosmo Pharmaceuticals Cancels Dr. Falk Pharma's EU License for Travelers' Diarrhea Drug	23-09-04	MT
Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023	23-07-26	CI
Transcript : Cosmo Pharmaceuticals N.V., H1 2023 Earnings Call, Jul 26, 2023	23-07-26
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-26	CI
Cosmo Pharmaceuticals Posts Lower H1 Post-tax Profit; Revenue Rises	23-07-26	MT

Chart Cosmo Pharmaceuticals N.V.

Duration

Period

More charts

Company Profile

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellersâ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Cosmo Pharmaceuticals N.V.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

72.5 EUR

Average target price

94.95 EUR

Spread / Average Target

+30.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
COSMO PHARMACEUTICALS N.V.	+39.10%	1.25B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Pharmaceuticals

EQS-Adhoc : Cosmo Full-Year Report 2020: Cosmo -2-

EPS Revisions